Navigation Links
Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures
Date:7/23/2014

rs) with partial-onset seizures not fully controlled despite treatment with 1-2 concomitant AEDs.4

N01253: an evaluation of the efficacy and safety/tolerability of adjunctive brivaracetam at doses of 5, 20, and 50 mg/day compared with placebo over 12 weeks, in 400 randomized patients (greater than or equal to 16 to 70 years) with partial-onset seizures, not fully controlled despite treatment with 1-2 concomitant AEDs.5

N01254: an evaluation of the safety and tolerability of adjunctive brivaracetam given at individualized tailored doses between 20 and 150 mg/day, compared with placebo over 16 weeks, in 480 randomized patients (greater than or equal to 16 to 70 years) with uncontrolled epilepsy (up to 20% could be patients with generalized epilepsy), not fully controlled despite treatment with 1-3 concomitant AEDs.6 N01358: an evaluation of the efficacy and safety of adjunctive brivaracetam 100 and 200 mg/day compared with placebo over 12 weeks in 768 randomized patients (greater than or equal to 16 to 80 years) with partial-onset seizures, not fully controlled despite treatment with 1-2 concomitant AEDs.2,7

About Epilepsy10,11,12Epilepsy is a chronic neurological disorder affecting approximately 65 million people worldwide. It is considered to be a disease of the brain defined by any of the following conditions: (1) at least two unprovoked (or reflex) seizures occurring >24 hours apart; (2) one unprovoked (or reflex) seizure and a probability of further seizures similar to the general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 10 years; (3) diagnosis of an epilepsy syndrome.

Although epilepsy may be linked to factors such as health conditions, race and age, it can develop in anyone at any age, and approximately 1 in 26 people will develop epilepsy in their lifetime. Partial seizures begin with an electrica
'/>"/>

SOURCE UCB
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Majority of Biotech/Pharma Employees Poised to Job Hunt
2. ZenCash Plucks Top Executives from Major DFW Brands
3. Accelerated Cure Project for Multiple Sclerosis Approved for Major Funding Award from Patient-Centered Outcomes Research Institute to Create MS Patient-Powered Research Network
4. Clinovo Rolls Out Major Enhancements for Open Source EDC ClinCapture at Outsourcing in Clinical Trials West Coast Conference
5. Verified Clinical Trials Stops Dual Enrollment in Clinical Trials in Major CNS Clinical Trials to Reduce Potential Adverse Events and Improve Data Quality
6. Major CRO Gives Top Ratings To Verified Clinical Trials To Stop Dual Enrollment In Clinical Trials On Late Phase Trial
7. Kibow Biotech Achieves Major Victory with Indias IPAB Decision to Uphold 2009 Product Patent
8. Sales Momentum Introduces 5 Payoffs to Asking Questions in Sales Calls in a White Paper - Mastering Major Account Selling
9. Dyadic International To Present At Two Major Conferences In December 2013
10. Sales Momentum Shares Three Common Pitfalls to Avoid When Developing Major Account Sales Strategies
11. The Blazing Diamond and the Quantum Jewel: Two Major Discoveries in Quick Succession
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic ... it has received a $1.5M Phase II SBIR ... to further develop its therapeutic agent to reduce ... need in end stage renal disease (ESRD) patients ... National Institute of Diabetes and Digestive and Kidney ...
(Date:8/26/2015)... After litigating and negotiating patent infringement ... P2i United States patent RE43,651 (the ... the United States without any admission or ... party. As a result of the parties, settlement, the US ... dismissed the case without prejudice. Under ...
(Date:8/25/2015)... , Aug. 25, 2015   WuXi PharmaTech (Cayman) ... capability and technology platform company serving the pharmaceutical, biotechnology, ... ("Lee,s Pharm," Hong Kong Exchange Stock Code: 0950), a ... with 20 years of operations in ... companies have signed an agreement whereby WuXi,s Laboratory Testing ...
(Date:8/25/2015)... ... 2015 , ... One of the world’s foremost authorities on supply chain risk ... been on a mission for the past two weeks. She’s been scrambling to warn ... the two massive explosions that occurred on August 12 at the Ruihai International Logistics ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3P2i Settles United States Litigation 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 2Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 3Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 4
... Systems Inc.,(Amex: PLC ) today announced that it ... dated September 17, 2008 from the Listing,Qualifications Department staff ... Company was not in compliance with Section 1003(a)(ii) of,the ... less,than $4,000,000 as of June 30, 2008, and it ...
... 18 SyntheMed, Inc. (OTC,Bulletin Board: SYMD), a ... anti-adhesion, drug delivery products and other,surgical implants, announced ... the,AdvaMed 2008 MedTech conference being held in Washington, ... and CEO of SyntheMed, is scheduled,to present on ...
... NOVATO, Calif., Sept. 18 BioMarin,Pharmaceutical Inc. (Nasdaq: ... article released by Bloomberg this morning. The article ... Chief Executive Officer of,BioMarin, held on September 17, ... is consistent with the,information previously released publicly:, ...
Cached Biology Technology:PLC Systems Receives Delisting Notice From American Stock Exchange 2SyntheMed To Present at the AdvaMed 2008 MedTech Conference 2BioMarin Corrects Information Included in Bloomberg Article 2BioMarin Corrects Information Included in Bloomberg Article 3
(Date:8/5/2015)... , August 5, 2015 ... titled "Facial Recognition Market - Global Industry Analysis, Size, ... global market for facial recognition is forecast to reach ... by increased demand for surveillance systems by civil and ... number of crimes and terrorist activities across the globe ...
(Date:8/4/2015)... 4, 2015  AMRI (NASDAQ: AMRI ) today reported financial ... Highlights: , Second quarter contract revenue of ... , Adjusted contract margins of 26 ... including a $0.05 decrease in EPS from royalties in the current ... "We are very pleased to present another strong ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 ... sobre Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 ... . La conferencia celebra su décimo ... se ha convertido en una de las reuniones anuales ... ,ómicas, y es una de las conferencias científicas más ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... farming and the introduction of new crops relies on ... climate change. Basing their argument on evolutionary, ecological, genetic ... Eshkol School of Agriculture at the Hebrew University of ... not the likely cause of plant domestication in the ...
... products to save the planet? That,s the question behind ... for carbon-producing activities (such as flying), with the idea ... funding for alternative energy sources. At the same time, ... would be the most effective means through which the ...
... One year in to a project to save one of ... being revealed for the first time. Scientists from Queen ... discovered an astonishing variety of minute aquatic organisms, so small ... Stoke Fen nature reserve is coming under the microscope of ...
Cached Biology News:Stable climate and plant domestication linked 2You say offset, I say tax? Study suggests labels and political affiliation may affect preferences 2Scientists find amazing new pondlife on nature reserve 2
MpV17 transgene, murine homolog, glomerulosclerosis...
... Ambion's custom siRNA service provides the ... gene silencing research. Custom siRNAs can be ... 19-21 base target sequence, or by providing ... check out Ambion's Silencer Validated and Silencer ...
Human SDNSF/MCFD2 Biotinylated Affinity Purified PAb...
8.1.1...
Biology Products: